Case Report

Leptomeningeal Enhancement due to Neurosarcoidosis Mimicking Malignancy

Sahara N. Saltijeral,1,2 Horiana B. Grosu,2 Henrique De La Garza,1,2 Barbara O’Brien,3 and Gloria Iliescu4

1Department of Internal Medicine, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Mexico
2Departments of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence should be addressed to Horiana B. Grosu; hbgrosu@mdanderson.org

Received 28 January 2020; Revised 25 March 2020; Accepted 31 March 2020; Published 21 April 2020

Academic Editor: Georgios D. Kotzalidis

Copyright © 2020 Sahara N. Saltijeral et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present report describes the case of a 56-year-old African American man experiencing progressive disequilibrium, lower extremity weakness, difficulty walking, and hearing loss. Brain magnetic resonance imaging showed leptomeningeal enhancement. Initial differential diagnosis was broad, including malignant, infectious, and inflammatory etiologies. The cerebrospinal fluid analyses demonstrated lymphocytic pleocytosis, hypoglycorrhachia, and hyperproteinorrachia but no other abnormalities. An extensive infectious disease workup was negative. Positron emission tomography revealed hypermetabolic lymph nodes in the right mediastinum and right hilum, correlating with findings on endobronchial ultrasonography. Subsequently, image-guided fine-needle aspiration of the right upper paratracheal lymph node was performed, and biopsy studies showed noncaseating granulomatous inflammation. Based on the clinical picture, the diagnosis of neurosarcoidosis was made, and high-dose steroids were started and resulted in significant improvement.

1. Introduction

Sarcoidosis is an idiopathic, noninfectious inflammatory disorder characterized by formation of noncaseating granulomas [1, 2]. The annual incidence is highest among African Americans, with 39.1 and 29.8 cases per 100,000 in females and males, respectively [3]. Imaging findings suggestive of neurosarcoidosis are found in 10% of patients with systemic sarcoidosis, and among these patients, only 5% develop symptoms [1, 3, 4]. Meningeal disease, which occurs in 10% to 20% of patients with neurosarcoidosis, usually presents as aseptic meningitis [5]. Meningeal disease in sarcoidosis may present as abnormal leptomeningeal enhancement, meningeal mass lesion, or dural mass lesion on MRI examination. In addition, meningeal sarcoidosis presenting as a mass on imaging can mimic intracranial tumors such as meningiomas. The case presented here, in which meningeal neurosarcoidosis mimicked malignancy, illustrates the diagnosis of this rare condition.

2. Case Report

A 56-year-old African American man presented complaining of progressive disequilibrium, lower extremity weakness, difficulty walking, and hearing loss over a 2-year period. On physical examination, he was found to have a mildly unsteady casual tandem gait. There were no cranial nerve deficits aside from slightly decreased hearing according to a bilateral finger rub test. Mildly decreased pinprick sensation was seen in the bilateral distal lower extremities. The patient’s bilateral hip flexion/extension was graded 4/5; otherwise, his strength was graded 5/5 in all 4
extremities. His symmetric reflexes were graded 3/4 in all extremities. Neither magnetic resonance imaging (MRI) nor computed tomography revealed abnormal findings at initial presentation. A lumbar puncture was performed, and the cerebrospinal fluid (CSF) analyses demonstrated lymphocytic pleocytosis, hypoglycorrhachia, and hyperproteinorrachia but no other abnormalities. Infectious disease workup was negative.

Later, the patient’s symptoms progressed, and repeat brain MRI performed two months after his initial presentation showed leptomeningeal enhancement that raised concerns of malignancy; however, infectious and inflammatory etiologies were in the differential as well. Subsequent brain MRI performed two months later exhibited nodular leptomeningeal enhancement overlying the superior cerebellum, interpeduncular cistern, frontal region, superior temporal lobe, periventricular region, near the obex, and in the left internal auditory canal (Figures 1(a) and 1(b)). Spine MRI showed diffuse multilevel nodular and plaque-like areas of enhancement along the surface of the cervical cord (Figure 2). Positron emission tomography (PET) showed hypermetabolic lymph nodes in the right upper and lower paratracheal lymph nodes, right hilum, and subcarinal lymph nodes (Figures 3(a) and 3(b)). Subsequent CSF analyses revealed leukocytosis, hypoglycorrhachia, hyperproteinorrachia, and angiotensin-converting enzyme (ACE, 8.6 U/L). Endobronchial ultrasonography showed enlarged lymph nodes corresponding to the PET imaging (Figures 4(a) and 4(b)). Image-guided fine-needle aspiration of the right upper paratracheal lymph node was performed subsequently, and the biopsy analyses showed noncaseating granulomatous inflammation.

Neurologic examination performed three months after the patient’s initial presentation showed clinical decline with mild cognitive difficulties, right foot weakness, decreased pinprick sensation in the feet with preserved vibratory sense, proprioception without alterations, and hyperreflexia. The patient developed sensory stocking-glove distribution neuropathy and increasing gait unsteadiness. Spine and brain MRI performed at this time showed worsening of the leptomeningeal enhancement.

On the basis of the workup, the patient was diagnosed with probable neurosarcoidosis, and high-dose steroids were started. At a follow-up visit one month after the start of steroid treatment, the patient had responded adequately; in particular, his strength and gait had notably improved. Subsequent spine and brain MRI showed near-complete resolution of the nodular leptomeningeal enhancement.

3. Discussion

Sarcoidosis can affect any organ system and present in virtually any manner [6]. The lungs or thoracic lymph nodes are involved in up to 90% of patients. Although only 10% of patients with systemic sarcoidosis have imaging findings suggestive of neurosarcoidosis—and few of these patients...
develop symptoms [3]—autopsy studies found central nervous system involvement in 15% to 20% of systemic sarcoidosis cases [5]. These postmortem studies have advanced the understanding of the pathogenesis of neurosarcoidosis, demonstrating that granulomatous dissemination can follow hematogenous or lymphatic routes as well as local extension. Presumably, hematogenous dissemination is the preferred route in the central nervous system [5]. Because brain neurosarcoidosis usually presents as an extensive variety of nonspecific symptoms, exclusion of other diagnoses is mandatory [3].

In a prospective study by Kidd [7], from a total of 166 patients with a “highly probable” diagnosis of neurosarcoidosis according to the World Association of Sarcoidosis and Other Granulomatous Diseases sarcoidosis organ assessment instrument, 67 patients presented involvement of leptomeninges and 42 patients presented with encephalopathy with headache, drowsiness, and cognitive slowing. Of these 42 patients, 17 had seizures and 8 had hydrocephalus and a brainstem syndrome with ataxia of gait, diplopia, and vertigo. In the same study, lesions in the spinal cord were seen in 28 patients.

Sarcoidosis is diagnosed on the basis of compatible findings from clinical examination and imaging studies, and the diagnosis is reinforced by histologic findings of non-caseating epithelioid-cell granulomas, in at least 1 organ, in the absence of organisms or particles [8]. Meningeal involvement in neurosarcoidosis can appear as nodular or diffuse leptomeningeal enhancement on contrast-enhanced T1-weighted MRI [2]. An important part of the initial CSF examination is to rule out infections, central nervous system disease, and malignancy [3]. Our patient went through an extensive infectious disease workup, including fungal, viral, and bacterial screens to exclude other compatible diagnoses. In patients with neurosarcoidosis, CSF examination generally exhibits a picture of chronic lymphocytic meningitis.
with lymphocyte predominance, hyperproteinorrachia, and hypoglycorrhachia. [4] Our patient’s CSF analyses showed 42 C/mL white blood cells, glucose <30 mg/dl, proteins >600 mg, and an ACE level of 8.6 unit/L. A high level of ACE in the CSF has a low sensitivity (between 24% and 55%) but high specificity (around 94%) for neurosarcoidosis and therefore may raise suspicion of the disease [2]. FDG-PET can reveal areas of hypermetabolism that correspond to active lesions in asymptomatic sites, which can be used to identify suitable sites to perform a biopsy [2]. Our patient’s PET demonstrated hypermetabolic right paratracheal lymph nodes, from which the biopsy was taken. Histopathologically, neurosarcoidosis is characterized by the presence of noncaseating epithelioid granulomas, the same lesions as those found elsewhere in the body in cases of systemic disease [2, 3]. Our patient’s biopsy showed anthracotic pigmented-laden macrophages and aggregates of epithelioid histocytes, suggestive of noncaseating granulomatous inflammation. Given the clinical picture, the probable diagnosis was made.

Treatment of neurosarcoidosis is based on general consensus, given that there are no established guidelines [2]. Corticosteroids are a mainstay in the treatment of neurosarcoidosis and are used as first-line agents unless severely contraindicated [4]. Our patient responded satisfactorily to high-dose steroids, resulting in improvement of radiological abnormalities.

**Abbreviations**

ACE: Angiotensin-converting enzyme  
CSF: Cerebrospinal fluid  
FDG: Fluorodeoxyglucose  
PET: Positron emission tomography  
MRI: Magnetic resonance imaging.

**Conflicts of Interest**

The authors have no conflicts of interest to disclose. These images have not been previously used.

**Acknowledgments**

Editorial support was provided by Bryan Tutt in Scientific Publications Services, Research Medical Library.

**References**

[1] G. Bathla, A. K. Singh, B. Policeni, A. Agarwal, and B. Case, “Imaging of neurosarcoidosis: common, uncommon, and rare,” *Clinical Radiology*, vol. 71, no. 1, pp. 96–106, 2016.
[2] S. Camões, “Neurosarcoidosis: a review of the state of art,” *Research and Reviews on Healthcare: Open Access Journal*, vol. 2, no. 1, 2018.
[3] C. Tana, S. Wegener, E. Borys et al., “Challenges in the diagnosis and treatment of neurosarcoidosis,” *Annals of Medicine*, vol. 47, no. 7, pp. 576–591, 2015.
[4] F. Bagnato and B. J. Stern, “Neurosarcoidosis: diagnosis, therapy and biomarkers,” *Expert Review of Neurotherapeutics*, vol. 15, no. 5, pp. 533–548, 2015.
[5] G. Bathla, P. Watal, S. Gupta, P. Nagpal, S. Mohan, and T. Moritani, “Cerebrovascular manifestations of neurosarcoidosis: an underrecognized aspect of the imaging spectrum,” *American Journal of Neuroradiology*, vol. 39, no. 7, pp. 1194–1200, 2017.
[6] A. O’regan and J. S. Berman, “Sarcoidosis,” *Annals of Internal Medicine*, vol. 156, no. 9, p. ITCS, 2012.
[7] D. P. Kidd, “Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results,” *Journal of Neurology*, vol. 265, no. 8, pp. 1906–1915, 2018.
[8] M. C. Iannuzzi, B. A. Rybicki, and A. S. Teirstein, “Sarcoidosis,” *New England Journal of Medicine*, vol. 357, no. 21, pp. 2153–2165, 2007.